Hematological consequences of a FANCG founder mutation in Black South African patients with Fanconi anemia

Blood Cells Mol Dis. 2015 Mar;54(3):270-4. doi: 10.1016/j.bcmd.2014.11.011. Epub 2014 Nov 27.

Abstract

Fanconi anemia (FA) is a rare disorder of DNA repair, associated with various somatic abnormalities but characterized by hematological disease that manifests as bone marrow aplasia and malignancy. The mainstay of treatment, in developed nations, is hematopoietic stem cell transplantation (HSCT) with subsequent surveillance for solid organ and non-hematological malignancies. In South Africa, FA in the Black population is caused by a homozygous deletion mutation in the FANCG gene in more than 80% of cases. Many affected patients are not diagnosed until late in the disease course when severe cytopenia and bone marrow aplasia are already present. Most patients are not eligible for HSCT at this late stage of the disease, even when it is available in the state health care system. In this study, the hematological presentation and disease progression in 30 Black South African patients with FA, confirmed to have the FANCG founder mutation, were evaluated and compared to those described in other FA cohorts. Our results showed that patients, homozygous for the FANCG founder mutation, present with severe cytopenia but progress to bone marrow failure at similar ages to other individuals affected with FA of heterogeneous genotype. Further, the incidence of myelodysplastic syndrome is similar to that which has been previously described in other FA cohorts. Although severe cytopenia at presentation may be predicted by a higher number of somatic anomalies, the recognition of the physical FA phenotype in Black South African patients is challenging and may not be useful in expediting referral of suspected FA patients for tertiary level investigations and care. Given the late but severe hematological presentation of FA in Black South African patients, an investigative strategy is needed for earlier recognition of affected individuals to allow for possible HSCT and management of bone marrow disease.

Keywords: Black South African patients; Bone marrow aplasia; FANCG founder mutation; Fanconi anemia; Hematopoietic stem cell transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Black People / genetics
  • Child
  • Child, Preschool
  • Cohort Studies
  • Fanconi Anemia / blood*
  • Fanconi Anemia / epidemiology
  • Fanconi Anemia / genetics*
  • Fanconi Anemia / therapy
  • Fanconi Anemia Complementation Group G Protein / genetics*
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Homozygote
  • Humans
  • Male
  • Middle Aged
  • Sequence Deletion*
  • South Africa / epidemiology

Substances

  • FANCG protein, human
  • Fanconi Anemia Complementation Group G Protein